Compass Pathways PLC
Change company Symbol lookup
Select an option...
CMPS Compass Pathways PLC
PAYS Paysign Inc
ALTR Altair Engineering Inc
CVX Chevron Corp
ASCB ASPAC II Acquisition Corp
STRS Stratus Properties Inc
ESMC Escalon Medical Corp
ATO Atmos Energy Corp
LVS Las Vegas Sands Corp
HUBB Hubbell Inc
Go

Health Care : Biotechnology |
Based in United Kingdom
Company profile

COMPASS Pathways plc is a United Kingdom-based mental healthcare company. The Company is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression (TRD). The Company has developed COMP360, which is a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin. The Company's COMP360 has completed a Phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. Its randomized controlled Phase IIb study of psilocybin therapy in treatment-resistant depression is the psilocybin therapy clinical trial, with approximately 233 patients across 22 sites in 10 European and North American countries. This trial assessed the safety and efficacy of COMP360 psilocybin therapy in three doses: 1mg, 10mg, 25mg. The Company is also running a Phase II clinical trial of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD).

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$10.73
Day's Change
-0.24 (-2.19%)
Bid
--
Ask
--
B/A Size
--
Day's High
11.30
Day's Low
10.46
Volume
(Heavy Day)
Volume:
554,844

10-day average volume:
355,965
554,844

Company Profile

COMPASS Pathways plc is a United Kingdom-based mental healthcare company. The Company is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression (TRD). The Company has developed COMP360, which is a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin. The Company's COMP360 has completed a Phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. Its randomized controlled Phase IIb study of psilocybin therapy in treatment-resistant depression is the psilocybin therapy clinical trial, with approximately 233 patients across 22 sites in 10 European and North American countries. This trial assessed the safety and efficacy of COMP360 psilocybin therapy in three doses: 1mg, 10mg, 25mg. The Company is also running a Phase II clinical trial of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD).

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
2.18x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

September 2022
Current Month
3.9M
Previous Month
3.6M
Percent of Float
17.72%
Days to Cover
11.8665 Days

Share Information

CMPS is in a share class of depositary receipt
Float
6.7M
Shares Outstanding
42.5M
Institutions Holding Shares
122
16.86%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • George GoldsmithChmn.
  • Michael FalveyCFO
  • Matthew OwensCounsel
  • Ekaterina MalievskaiaOther
  • Guy GoodwinOther

Address

Insider Trading

During the most recent quarter, 32K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.